Reshma Kewalramani Is Guiding Vertex Pharmaceuticals to Its Next Big Thing

Under her predecessor, Vertex revolutionized the treatment of cystic fibrosis. Kewalramani’s job is to maintain that franchise while guiding Vertex to its next big thing. There are plenty of options: Vertex is developing a pain medicine called suzetrigine that could satisfy enormous demand for a nonopioid pain reliever, and a stem-cell-derived therapy called VX-880 that the company hopes will be a cure for Type 1 diabetes, among many programs.